News

Insights from CROI on the HepB-CpG vaccine trial.

Biomarkers associated with mortality differed by sex and there may be distinct pathophysiologic mechanisms that account for the increased risk seen in females, according to investigators.

Unraveling monocyte activation and the implications for cardiovascular risk

A reduced risk of individual symptoms associated with the condition was reported when patients were administered the therapy within 2 days of admittance.

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.

A National Institutes of Health (NIH) sponsored study reveals a need for more accurate screening in Black people and cisgender women.

Study shows high efficacy of a 4-week glecaprevir/pibrentasvir regimen for shorter, more manageable treatment duration.

The American Gastroenterological Association guidelines navigating fecal microbiota transplantation in clinical practice.

In a phase 1 study, the investigational therapy known as cabotegravir ultra long-acting (CAB-ULA), showed positive pharmacokinetic, tolerability, and safety data supporting a prospective move to the next stage of clinical development.

Study presented at CROI 2024 reveals that the introduction of Doxycycline post-exposure prophylaxis (doxy-PEP) guidelines in San Francisco has significantly decreased the incidence of chlamydia and syphilis

A new study offers some clues into the pathophysiology and biomarkers of post-acute Sequelae of SARS-CoV-2 (PASC).

Study dives into the complexities of using Oral Vancomycin Prophylaxis to combat Clostridioides difficile in hematopoietic stem cell transplantation recipients with insights from researcher Alexander Vartanov, MD.

From the ongoing CROI meeting, the FDA approved antiretroviral was studied over a 2-year period and showed treatment benefit.

In thinking about the international and national public health campaigns to eliminate hepatitis, is general awareness of the disease enough to motivate treatment-hesitant hepatitis patients to accept clinical care, or does there need to be a greater commitment beyond that?

The company released top-line data for its Abrysvo vaccine, demonstrating efficacy against respiratory syncytial virus (RSV) in adults aged 60 and older.

This week, why measles and vibrio vulnificus infections are seeing outbreaks and increases in incidence rates; a medical association recommends fecal microbiota-based therapies for recurrent or severe C difficile; and an antiviral reduced a median time-to-symptom resolution.

Norovirus cases rise in the northeast and are spreading across the nation.

Reduced childhood immunizations because of personal beliefs and fears, and the quarantine's effect, along with a lack of knowledge about transmissibility and the seriousness of measles are causing unnecessary suffering and danger to people, especially in children.

Novavax's Robert Walker, MD emphasizes protective health strategies highlighting the importance of COVID-19 vaccination for hypertensive individuals.

Over 1 billion people are estimated to be affected by 20 conditions of neglected tropical diseases (NTDs), though they are often unheard of by many. Heather Saunders, MPH, RN, CIC, delves into 5 of these diseases and discusses efforts to stop their spread.

With today's vote, the federal agency’s Advisory Committee on Immunization Practices (ACIP) is now recommending people 65 years of age and older get 1 more dose of the 2023-2024 formula of the COVID-19 vaccine.

Promising oral antibiotic candidate for the treatment of uncomplicated urogenital gonorrhea

New insights challenge assumptions on SARS-CoV-2 immunity duration.

Study exposes the adherence gap in HCV direct-acting antiviral therapy among people who inject drugs.

A new paper outlines how these variables can be connected to create situations where patients get less-than-optimal outcomes.

Trial demonstrates promising results for oral treatment towards the disease's vector.

The new indication for bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF (Biktarvy) is for patients with suppressed viral loads, pre-existing resistance.

A rise in cases of the waterborne pathogen.